Related Experiment Video

Updated: Jul 6, 2026

Cardiac Pressure-Volume Loop Analysis Using Conductance Catheters in Mice
08:15

Cardiac Pressure-Volume Loop Analysis Using Conductance Catheters in Mice

Published on: September 17, 2015

Uniformity of captopril benefit in the SAVE Study: subgroup analysis. Survival and Ventricular Enlargement Study

L A Moyé1, M A Pfeffer, C C Wun

  • 1Brigham and Women's Hospital, Cardiovascular Division, Boston, MA 02115.

European Heart Journal
|May 1, 1994
PubMed

Insights

The Survival and Ventricular Enlargement (SAVE) Study found that captopril, an angiotensin-converting enzyme inhibitor, reduced cardiovascular death and illness in heart attack survivors with left ventricular dysfunction. Benefits were consistent across various patient subgroups.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Left ventricular dysfunction post-myocardial infarction (MI) increases cardiovascular risk.
  • Angiotensin-converting enzyme (ACE) inhibitors are a therapeutic class for cardiovascular conditions.

Purpose of the Study:

  • To evaluate the long-term effects of captopril in recent survivors of myocardial infarction with left ventricular dysfunction.
  • To assess the efficacy of captopril in reducing cardiovascular mortality and morbidity across diverse patient subgroups.

Main Methods:

  • The Survival and Ventricular Enlargement (SAVE) Study involved long-term administration of captopril.
  • Analysis included subgroup evaluations based on demographics and clinical characteristics.

Main Results:

  • Captopril significantly reduced cardiovascular mortality and morbidity.
  • Benefits of captopril were observed consistently across various patient subgroups, including those with higher baseline cardiovascular risk.
  • Subgroup analyses indicated greater event rates in higher-risk groups, irrespective of therapy.

Conclusions:

  • Long-term captopril therapy is effective in reducing cardiovascular mortality and morbidity in post-MI patients with left ventricular dysfunction.
  • The benefits of captopril are broadly applicable and not limited to specific subgroups.
  • Treatment should target the widest possible group meeting SAVE study entry criteria for maximal cardiovascular risk reduction.

More Related Videos

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

Establishment and Confirmation of a Postnatal Right Ventricular Volume Overload Mouse Model06:04

Establishment and Confirmation of a Postnatal Right Ventricular Volume Overload Mouse Model

Published on: June 9, 2023

Related Concept Videos

Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and Cox...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...